Bepirovirsen Approved: Chronic Hepatitis B Treatment Moves from Long-Term Viral Suppression Toward Functional Cure
On August 24, 2026, Japan’s Ministry of Health, Labour and Welfare approved bepirovirsen (development code GSK3228836, commonly abbreviated as GSK836), developed by GSK and marketed under the brand name Hibsago, for functional cure in eligible adults with persistent hepatitis B virus infection. ...
危险品化学品经营许可证（带存储）